Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...

Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...

Miltenyi Biotec launches India's first dedicated Cell and Gene Therapy Center of Excellence in Hyderabad, aiming to advance ...

Miltenyi Biotec opens cell & gene therapy centre in Genome Valley, advancing innovation in combating diseases like cancer.

Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data ...

Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Miltenyi Biotec launched India's first Cell and Gene Therapy Center in Hyderabad. The Miltenyi Innovation and Technology ...

Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...